Bayesian Model Averaging Continual Reassessment Method BMA-CRM
نویسندگان
چکیده
This document provides the statistical background for the Bayesian model averaging continual reassessment method (BMA-CRM). The BMA-CRM is a Bayesian model-based phase I clinical trial design. The primary goal of the BMA-CRM is to identify the maximum tolerated dose (MTD) of a new drug, which is typically defined as the dose with a doselimiting toxicity (DLT) probability that is closest to the target toxicity rate. We assume that the DLT is recorded as a binary outcome, and monotonically increases with respect to the dose level.
منابع مشابه
The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach
Grade information has been considered in Yuan et al. (2007) wherein they proposed a Quasi-CRM method to incorporate the grade toxicity information in phase I trials. A potential problem with the Quasi-CRM model is that the choice of skeleton may dramatically vary the performance of the CRM model, which results in similar consequences for the Quasi-CRM model. In this paper, we propose a new mode...
متن کاملBootstrap Aggregating Continual Reassessment Method for Dose Finding in Drug-combination Trials1 By
Phase I drug-combination trials are becoming commonplace in oncology. Most of the current dose-finding designs aim to quantify the toxicity probability space using certain prespecified yet complicated models. These models need to characterize not only each individual drug’s toxicity profile, but also their interaction effects, which often leads to multi-parameter models. We propose a novel Baye...
متن کاملRobust EM Continual Reassessment Method in Oncology Dose Finding.
The continual reassessment method (CRM) is a commonly used dose-finding design for phase I clinical trials. Practical applications of this method have been restricted by two limitations: (1) the requirement that the toxicity outcome needs to be observed shortly after the initiation of the treatment; and (2) the potential sensitivity to the prespecified toxicity probability at each dose. To over...
متن کاملBayesian Data Augmentation Dose Finding with Continual Reassessment Method and Delayed Toxicities
A major practical impediment when implementing adaptive dose-finding designs is that the toxicity outcome used by the decision rules may not be observed shortly after the initiation of the treatment. To address this issue, we propose the data augmentation continual reassessment method (DA-CRM) for dose finding. By naturally treating the unobserved toxicities as missing data, we show that such m...
متن کاملThe continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
We discuss the continual reassessment method (CRM) and its extension with practical applications in phase I and I/II cancer clinical trials. The CRM has been proposed as an alternative design of a traditional cohort design and its essential features are the sequential (continual) selection of a dose level for the next patients based on the dose-toxicity relationship and the updating of the rela...
متن کامل